deferasirox has been researched along with Kidney Diseases in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 11 (91.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bruederle, A; Castiglioni, C; Della Corte, G; Forni, GL; Han, J; Origa, R; Piga, A; Tartaglione, I | 1 |
| Alimena, G; Breccia, M | 1 |
| Alizadeh, S; Bamedi, T; Dorgalaleh, A; Jahantigh, A; Naderi, M; Sadeghi-Bojd, S; Tabibian, S; Valeshabad, AK | 1 |
| Chan, GC; Cheuk, DK; Chiang, AK; Dee, CM; Ha, SY | 1 |
| Erman, A; Feige Gross Nevo, R; Gafter, U; Gafter-Gvili, A; Milo, G; Pazgal, I; Shpilberg, O; Stark, P | 1 |
| Athanassiou-Metaxa, M; Economou, M; Papachristou, F; Printza, N; Teli, A; Tsatra, I; Tzimouli, V | 1 |
| López-Hernandez, FJ; López-Novoa, JM; Macías-Nuñez, JF; Morales, AI; Sánchez-González, PD | 1 |
| Cochat, P; Dubourg, L; Hadj-Aïssa, A; Laurain, C; Pondarré, C; Ranchin, B; Sigaudo-Roussel, D | 1 |
| Alimena, G; Breccia, M; Colafigli, G; Federico, V; Finsinger, P; Latagliata, R; Loglisci, G; Petrucci, L; Salaroli, A; Santopietro, M; Serrao, A | 1 |
| Bhandari, S; Daar, S | 1 |
| Aydinok, Y; Chan, LL; El-Beshlawy, A; Elalfy, MS; Habr, D; Lee, SH; Martin, N; Porter, JB; Sutcharitchan, P; Taher, AT | 1 |
| Vichinsky, E | 1 |
2 review(s) available for deferasirox and Kidney Diseases
| Article | Year |
|---|---|
Efficacy and safety of deferasirox in myelodysplastic syndromes.
Topics: Benzoates; Chelation Therapy; Clinical Trials, Phase II as Topic; Deferasirox; Drug Eruptions; Drug Therapy, Combination; Ferritins; Gastrointestinal Diseases; Humans; Iron; Iron Chelating Agents; Iron Overload; Kidney Diseases; Multicenter Studies as Topic; Myelodysplastic Syndromes; NF-kappa B; Oxidative Stress; Prospective Studies; Retrospective Studies; Survival Analysis; Transfusion Reaction; Triazoles | 2013 |
Clinical application of deferasirox: practical patient management.
Topics: Administration, Oral; Adult; Benzoates; Chemical and Drug Induced Liver Injury; Child; Clinical Trials as Topic; Contraindications; Creatinine; Deferasirox; Disease Management; Drug Eruptions; Gastrointestinal Diseases; Hematologic Diseases; Hemosiderosis; Humans; Iron; Iron Chelating Agents; Iron Overload; Kidney Diseases; Transfusion Reaction; Triazoles | 2008 |
2 trial(s) available for deferasirox and Kidney Diseases
| Article | Year |
|---|---|
Renal safety under long-course deferasirox therapy in iron overloaded transfusion-dependent β-thalassemia and other anemias.
Topics: Adolescent; Adult; Anemia; beta-Thalassemia; Blood Transfusion; Child; Creatinine; Deferasirox; Female; Follow-Up Studies; Humans; Iron Chelating Agents; Iron Overload; Kidney Diseases; Male; Middle Aged; Prospective Studies; Retrospective Studies; Young Adult | 2018 |
A prospective study of tubular dysfunction in pediatric patients with Beta thalassemia major receiving deferasirox.
Topics: Adolescent; Benzoates; beta-Thalassemia; Blood Transfusion; Child; Child, Preschool; Creatinine; Deferasirox; Female; Glomerular Filtration Rate; Humans; Iron Chelating Agents; Iron Overload; Kidney Diseases; Male; Metals; Prospective Studies; Triazoles | 2013 |
8 other study(ies) available for deferasirox and Kidney Diseases
| Article | Year |
|---|---|
Incidence of deferasirox-associated renal tubular dysfunction in children and young adults with beta-thalassaemia.
Topics: Adolescent; Alkalosis; Benzoates; beta 2-Microglobulin; beta-Thalassemia; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferiprone; Deferoxamine; Fanconi Syndrome; Female; Humans; Iron Chelating Agents; Kidney Diseases; Kidney Tubules; Male; Pyridones; Retrospective Studies; Transfusion Reaction; Triazoles; Water-Electrolyte Imbalance; Young Adult | 2014 |
GFR in Patients with β-Thalassemia Major.
Topics: Adult; Benzoates; beta-Thalassemia; Biomarkers; Creatinine; Deferasirox; Female; Glomerular Filtration Rate; Humans; Inulin; Iron Chelating Agents; Israel; Kidney; Kidney Diseases; Male; Models, Biological; Outpatient Clinics, Hospital; Predictive Value of Tests; Reproducibility of Results; Transfusion Reaction; Triazoles; Young Adult | 2015 |
Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox.
Topics: Adolescent; Adult; Benzoates; beta 2-Microglobulin; beta-Thalassemia; Biomarkers; Chelation Therapy; Child; Child, Preschool; Cystatin C; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Early Diagnosis; Female; Humans; Hypercalciuria; Iron Chelating Agents; Kidney Diseases; Kidney Function Tests; Male; Proteinuria; Pyridones; Triazoles; Young Adult | 2010 |
Effects of deferasirox on renal function and renal epithelial cell death.
Topics: Acetylglucosaminidase; Animals; Apoptosis; Benzoates; Cell Adhesion Molecules; Cell Line; Chick Embryo; Clusterin; Cystatin C; Deferasirox; Epithelial Cells; Glomerular Filtration Rate; Histocytochemistry; Iron Chelating Agents; Kidney; Kidney Diseases; Lipocalins; Male; Rats; Rats, Wistar; Triazoles | 2011 |
Deferasirox-induced renal impairment in children: an increasing concern for pediatricians.
Topics: Administration, Oral; Adolescent; Age Factors; Benzoates; Child; Deferasirox; Female; Glomerular Filtration Rate; Humans; Inulin; Iron Chelating Agents; Iron Overload; Kidney Diseases; Kidney Glomerulus; Kidney Tubules, Proximal; Male; Prospective Studies; Time Factors; Transfusion Reaction; Triazoles | 2012 |
Deferasirox treatment for myelodysplastic syndromes: "real-life" efficacy and safety in a single-institution patient population.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites; Azacitidine; Benzoates; Chelating Agents; Deferasirox; Drug Eruptions; Drug Evaluation; Drug Therapy, Combination; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematinics; Humans; Iron Overload; Kidney Diseases; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Thalidomide; Treatment Outcome; Triazoles | 2012 |
Deferasirox and renal dysfunction in children.
Topics: Benzoates; Deferasirox; Female; Humans; Iron Chelating Agents; Kidney Diseases; Kidney Glomerulus; Kidney Tubules, Proximal; Male; Triazoles | 2012 |
Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy.
Topics: Adolescent; Adult; Benzoates; Chelation Therapy; Child; Child, Preschool; Cholelithiasis; Clinical Trials, Phase III as Topic; Creatinine; Deferasirox; Edema; Ethnicity; Female; Ferritins; Gastrointestinal Diseases; Hematologic Diseases; Hepatitis, Viral, Human; Humans; Infant; Iron; Iron Chelating Agents; Iron Overload; Kidney Diseases; Liver; Magnetic Resonance Imaging; Male; Multicenter Studies as Topic; Prospective Studies; Thalassemia; Transfusion Reaction; Triazoles; Young Adult | 2013 |